BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29685422)

  • 21. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.
    Zou H; Yang R; Liao ZX; Qin TD; Chen P; Zhang BY; Cao YP; Huang HF
    J Clin Lab Anal; 2019 Mar; 33(3):e22827. PubMed ID: 30485557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extramedullary Waldenström macroglobulinemia.
    Banwait R; Aljawai Y; Cappuccio J; McDiarmid S; Morgan EA; Leblebjian H; Roccaro AM; Laubach J; Castillo JJ; Paba-Prada C; Treon S; Redd R; Weller E; Ghobrial IM
    Am J Hematol; 2015 Feb; 90(2):100-4. PubMed ID: 25349134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia.
    Terpos E; Anagnostopoulos A; Kastritis E; Bamias A; Tsionos K; Dimopoulos MA
    Br J Haematol; 2006 May; 133(3):301-4. PubMed ID: 16643432
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
    Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
    [No Abstract]   [Full Text] [Related]  

  • 28. Serum levels of total-RANKL in multiple myeloma.
    Jakob C; Goerke A; Terpos E; Sterz J; Heider U; Kühnhardt D; Ziefle S; Kleeberg L; Mieth M; Metzler Iv; Müller C; Sezer O
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):430-5. PubMed ID: 19951882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
    Ho AW; Hatjiharissi E; Ciccarelli BT; Branagan AR; Hunter ZR; Leleu X; Tournilhac O; Xu L; O'Connor K; Manning RJ; Santos DD; Chemaly M; Patterson CJ; Soumerai JD; Munshi NC; McEarchern JA; Law CL; Grewal IS; Treon SP
    Blood; 2008 Dec; 112(12):4683-9. PubMed ID: 18216294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
    Abeykoon JP; Zanwar S; Ansell SM; Winters J; Gertz MA; King RL; Murray D; Habermann T; Dingli D; Muchtar E; Go RS; Leung N; Inwards DJ; Buadi FK; Dispenzieri A; Lacy MQ; Lin Y; Gonsalves WI; Kourelis T; Witzig TE; Thompson C; Vincent Rajkumar S; Kyle RA; Kumar S; Kapoor P
    Am J Hematol; 2018 Nov; 93(11):1384-1393. PubMed ID: 30121949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Glucocorticoid and Bone. Significance of serum soluble RANKL measurement in patients under glucocorticoid therapy].
    Kaneko K; Kawai S
    Clin Calcium; 2014 Sep; 24(9):1361-70. PubMed ID: 25177009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.
    Elsawa SF; Novak AJ; Ziesmer SC; Almada LL; Hodge LS; Grote DM; Witzig TE; Fernandez-Zapico ME; Ansell SM
    Blood; 2011 Nov; 118(20):5540-9. PubMed ID: 21921047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia.
    Atrash S; Zhang Q; Papanikolaou X; Stein C; Abdallah AO; Barlogie B
    J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
    Baldini L; Goldaniga M; Guffanti A; Broglia C; Cortelazzo S; Rossi A; Morra E; Colombi M; Callea V; Pogliani E; Ilariucci F; Luminari S; Morel P; Merlini G; Gobbi P
    J Clin Oncol; 2005 Jul; 23(21):4662-8. PubMed ID: 16034042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
    Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
    Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
    Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
    Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience.
    Sajid R; Siddiqui SH; Shaikh U; Adil S
    Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.
    Cao X; Ye Q; Orlowski RZ; Wang X; Loghavi S; Tu M; Thomas SK; Shan J; Li S; Qazilbash M; Yin CC; Weber D; Miranda RN; Xu-Monette ZY; Medeiros LJ; Young KH
    J Hematol Oncol; 2015 Jun; 8():74. PubMed ID: 26104577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation.
    Merzianu M; Jiang L; Lin P; Wang X; Weber DM; Vadhan-Raj S; Nguyen MH; Medeiros LJ; Bueso-Ramos CE
    Mod Pathol; 2006 Jul; 19(7):891-8. PubMed ID: 16636680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
    Naderi N; Yang DT
    Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.